Sort   by:  
 Page size 
TranscriptomicsHuman HL-60 Cells: all-trans retinoic acid (ATRA) vs. ATRA plus arsenic trioxide (ATO)
Transcriptional profiling of human leukemia?HL-60 cells comparing ATRA treated HL-60 cells with ATRA plus ATO. Goal was to determine the effects of ATO on ATRA induced differentiation of HL-60 cells. Two-condition experiment, ATRA vs. ATRA plus ATO treated HL-60 cells.
ORGANISM(S): Homo sapiens 
2015-03-31 | E-GEOD-67420 | biostudies-arrayexpress
TranscriptomicsInhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21 [miRNA expression]
The epidemiologic association between statin use and decreased risk of advanced prostate cancer suggests that statins may inhibit prostate cancer development and/or progression. Studies were performed to determine the effects of a model statin, atorvastatin (ATO), on the proliferation and different...
ORGANISM(S): Homo sapiens 
2013-09-30 | E-GEOD-46375 | biostudies-arrayexpress
TranscriptomicsInhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21 [Gene expression]
The epidemiologic association between statin use and decreased risk of advanced prostate cancer suggests that statins may inhibit prostate cancer development and/or progression. Studies were performed to determine the effects of a model statin, atorvastatin (ATO), on the proliferation and different...
ORGANISM(S): Homo sapiens 
2013-09-30 | E-GEOD-46374 | biostudies-arrayexpress
GenomicsGene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines
Gene expression signatures for combined ATO and CDDP treatment (Ato-C) in CML cell lines
PRJNA413918 | ENA
GenomicsRNA sequencing of ATO clinical trial patients
RNAseq of ATO trial
PRJEB20631 | ENA
ProteomicsArsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells
Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) combination safely cures fatal acute promyelocytic leukemia, but the mechanisms underlying their action and synergy remain elusive. ATRA inhibits APL, breast and liver cancers by targeting isomerase Pin1, a master regulator of oncogenic signa...
ORGANISM(S): Homo sapiens (Human) 
2018-10-16 | PXD010224 | Pride
Ato Atra Synergy Pin1 
Transcriptomicshuman leukemia cell line K562 offspring acquring imatinib resistance(K562-r) : Control vs. Drug treated
Transcriptional profiling of K562-r comparing control untreated human leukemia cells with human leukemia cells treated with AMN107 and ATO individually or combined.Four timepoints included are 3h,12h,24h,48h, covering the whole time window of K562-r cells responsing to the drug treatment.At the comb...
ORGANISM(S): Homo sapiens 
2010-12-30 | E-GEOD-24946 | biostudies-arrayexpress
GenomicsGene expression profiles of ATO-treated and negative control cells
Gene expression profiles of ATO-treated and negative control cells
PRJNA527976 | ENA
TranscriptomicsTranscriptome array of Pml+/+ and Pml-/- mice APL cells treated with ATRA+ATO against untreated controls
This experiment aims at understanding the main transcriptomic basals differences between Pml+/+ and Pml-/- APL blasts and during ATRA+ATO treatment. Mice were transplanted were Pml+/+ or Pml-/- blasts. Once sick, mice were treated with 12 hours of ATRA+ATO therapy (ATRA: subcutaneous diffusion, ATO:...
ORGANISM(S): Mus musculus 
2025-01-01 | E-MTAB-13392 | biostudies-arrayexpress
ProteomicsArsenic Trioxide Acts as a Molecular Glue to Promote STUB1-Mediated NPM-ALK Degradation in ALK⁺ ALCL
The NPM-ALK fusion constitutively activates ALK tyrosine kinase, driving oncogenesis in anaplastic large cell lymphoma (ALCL). Although arsenic trioxide (ATO) exhibits therapeutic potential in NPM-ALK⁺ ALCL by inhibiting proliferation and inducing apoptosis, its molecular mechanism remains unclear. ...
ORGANISM(S): Homo sapiens (Human) 
2026-09-07 | PXD074054 | Pride
Karpas299 Ato Targeted protein degradation Npm-alk+ alcl 
Sort   by:  
 Page size